Russell Pieper, PhD
Professor
Neurological Surgery
School of Medicine

Brownstein Chair in Brain Tumor Research and Professor and Vice-Chairman of the UCSF Department of Neurological Surgery. He is also Director of Basic Research in the UCSF Brain Tumor Research Center and co-Leader of the Neuro-Oncology Program in the Helen Diller Family Comprehensive Cancer Center. His research has been independently funded by the National Institutes of Health and the National Cancer Institute since 1989 and is focused on the role signal transduction plays in the development and therapy of brain tumors. The laboratory is currently focused on how mutant IDH1 expression regulates telomere biology and contributes to the development of lower-grade glioma.

• Metabolic imaging detects elevated glucose flux through the pentose phosphate pathway associated with TERT expression in low-grade gliomas.
  Neuro-oncology 2021 Viswanath P, Batsios G, Ayyappan V, Taglang C, Gillespie AM, Larson PEZ, Luchman HA, Costello JF, Pieper RO, Ronen SM
• RETRACTED: A subset of PARP inhibitors induces lethal telomere fusion in ALT-dependent tumor cells.
  Science translational medicine 2021 Mukherjee J, Pandita A, Kamalakar C, Johannessen TC, Ohba S, Tang Y, Dalle-Ore CL, Bjerkvig R, Pieper RO
• Early Noninvasive Metabolic Biomarkers of Mutant IDH Inhibition in Glioma.
  Metabolites 2021 Radoul M, Hong D, Gillespie AM, Najac C, Viswanath P, Pieper RO, Costello JF, Luchman HA, Ronen SM
• Non-invasive assessment of telomere maintenance mechanisms in brain tumors.
  Nature communications 2021 Viswanath P, Batsios G, Mukherjee J, Gillespie AM, Larson PEZ, Luchman HA, Phillips JJ, Costello JF, Pieper RO, Ronen SM
• Glutamate Is a Noninvasive Metabolic Biomarker of IDH1-Mutant Glioma Response to Temozolomide Treatment.
  Cancer research 2020 Subramani E, Radoul M, Najac C, Batsios G, Molloy AR, Hong D, Gillespie AM, Santos RD, Viswanath P, Costello JF, Pieper RO, Ronen SM
• The Correlation of Fluorescence of Protoporphyrinogen IX and Status of Isocitrate Dehydrogenase in Gliomas.
  Neurosurgery 2020 Ohba S, Murayama K, Kuwahara K, Pareira ES, Nakae S, Nishiyama Y, Adachi K, Yamada S, Sasaki H, Yamamoto N, Abe M, Mukherjee J, Hasegawa M, Pieper RO, Hirose Y
• Patient-derived cells from recurrent tumors that model the evolution of IDH-mutant glioma.
  Neuro-oncology advances 2020 Jones LE, Hilz S, Grimmer MR, Mazor T, Najac C, Mukherjee J, McKinney A, Chow T, Pieper RO, Ronen SM, Chang SM, Phillips JJ, Costello JF
• MR-detectable metabolic biomarkers of response to mutant IDH inhibition in low-grade glioma.
  Theranostics 2020 Molloy AR, Najac C, Viswanath P, Lakhani A, Subramani E, Batsios G, Radoul M, Gillespie AM, Pieper RO, Ronen SM
• Phosphoglycerate Mutase 1 Activates DNA Damage Repair via Regulation of WIP1 Activity.
  Cell reports 2020 Ohba S, Johannessen TA, Chatla K, Yang X, Pieper RO, Mukherjee J
• PI3K/mTOR inhibition of IDH1 mutant glioma leads to reduced 2HG production that is associated with increased survival.
  Scientific reports 2019 Batsios G, Viswanath P, Subramani E, Najac C, Gillespie AM, Santos RD, Molloy AR, Pieper RO, Ronen SM
• Mutant and Wild-Type Isocitrate Dehydrogenase 1 Share Enhancing Mechanisms Involving Distinct Tyrosine Kinase Cascades in Cancer.
  Cancer discovery 2019 Chen D, Xia S, Wang M, Lin R, Li Y, Mao H, Aguiar M, Famulare CA, Shih AH, Brennan CW, Gao X, Pan Y, Liu S, Fan J, Jin L, Song L, Zhou A, Mukherjee J, Pieper RO, Mishra A, Peng J, Arellano M, Blum WG,…
• HDAC inhibition in glioblastoma monitored by hyperpolarized 13 C MRSI.
  NMR in biomedicine 2018 Radoul M, Najac C, Viswanath P, Mukherjee J, Kelly M, Gillespie AM, Chaumeil MM, Eriksson P, Delos Santos R, Pieper RO, Ronen SM
• Neurofibromin knockdown in glioma cell lines is associated with changes in cytokine and chemokine secretion in vitro.
  Scientific reports 2018 Wood MD, Mukherjee J, Pieper RO
• Mutant IDH1 gliomas downregulate phosphocholine and phosphoethanolamine synthesis in a 2-hydroxyglutarate-dependent manner.
  Cancer & metabolism 2018 Viswanath P, Radoul M, Izquierdo-Garcia JL, Luchman HA, Gregory Cairncross J, Pieper RO, Phillips JJ, Ronen SM
• Mutant IDH1 Cooperates with ATRX Loss to Drive the Alternative Lengthening of Telomere Phenotype in Glioma.
  Cancer research 2018 Mukherjee J, Johannessen TC, Ohba S, Chow TT, Jones L, Pandita A, Pieper RO
• 2-Hydroxyglutarate-Mediated Autophagy of the Endoplasmic Reticulum Leads to an Unusual Downregulation of Phospholipid Biosynthesis in Mutant IDH1 Gliomas.
  Cancer research 2018 Viswanath P, Radoul M, Izquierdo-Garcia JL, Ong WQ, Luchman HA, Cairncross JG, Huang B, Pieper RO, Phillips JJ, Ronen SM
• Mutant IDH1 Expression Drives TERT Promoter Reactivation as Part of the Cellular Transformation Process.
  Cancer research 2016 Ohba S, Mukherjee J, Johannessen TC, Mancini A, Chow TT, Wood M, Jones L, Mazor T, Marshall RE, Viswanath P, Walsh KM, Perry A, Bell RJ, Phillips JJ, Costello JF, Ronen SM, Pieper RO
• UBE2S, a novel substrate of Akt1, associates with Ku70 and regulates DNA repair and glioblastoma multiforme resistance to chemotherapy.
  Oncogene 2016 Hu L, Li X, Liu Q, Xu J, Ge H, Wang Z, Wang H, Wang Z, Shi C, Xu X, Huang J, Lin Z, Pieper RO, Weng C
• Rapid Conversion of Mutant IDH1 from Driver to Passenger in a Model of Human Gliomagenesis.
  Molecular cancer research : MCR 2016 Johannessen TA, Mukherjee J, Viswanath P, Ohba S, Ronen SM, Bjerkvig R, Pieper RO
• Mutant IDH1 expression is associated with down-regulation of monocarboxylate transporters.
  Oncotarget 2016 Viswanath P, Najac C, Izquierdo-Garcia JL, Pankov A, Hong C, Eriksson P, Costello JF, Pieper RO, Ronen SM
• PKM2 uses control of HuR localization to regulate p27 and cell cycle progression in human glioblastoma cells.
  International journal of cancer 2016 Mukherjee J, Ohba S, See WL, Phillips JJ, Molinaro AM, Pieper RO
• IDH1 Mutation Induces Reprogramming of Pyruvate Metabolism.
  Cancer research 2015 Izquierdo-Garcia JL, Viswanath P, Eriksson P, Cai L, Radoul M, Chaumeil MM, Blough M, Luchman HA, Weiss S, Cairncross JG, Phillips JJ, Pieper RO, Ronen SM
• Metabolic reprogramming in mutant IDH1 glioma cells.
  PloS one 2015 Izquierdo-Garcia JL, Viswanath P, Eriksson P, Chaumeil MM, Pieper RO, Phillips JJ, Ronen SM
• Changes in pyruvate metabolism detected by magnetic resonance imaging are linked to DNA damage and serve as a sensor of temozolomide response in glioblastoma cells.
  Cancer research 2014 Park I, Mukherjee J, Ito M, Chaumeil MM, Jalbert LE, Gaensler K, Ronen SM, Nelson SJ, Pieper RO
• Glioma cells with the IDH1 mutation modulate metabolic fractional flux through pyruvate carboxylase.
  PloS one 2014 Izquierdo-Garcia JL, Cai LM, Chaumeil MM, Eriksson P, Robinson AE, Pieper RO, Phillips JJ, Ronen SM
• Mutant IDH1-driven cellular transformation increases RAD51-mediated homologous recombination and temozolomide resistance.
  Cancer research 2014 Ohba S, Mukherjee J, See WL, Pieper RO
• Hyperpolarized [1-13C] glutamate: a metabolic imaging biomarker of IDH1 mutational status in glioma.
  Cancer research 2014 Chaumeil MM, Larson PE, Woods SM, Cai L, Eriksson P, Robinson AE, Lupo JM, Vigneron DB, Nelson SJ, Pieper RO, Phillips JJ, Ronen SM
• Lactate dehydrogenase A silencing in IDH mutant gliomas.
  Neuro-oncology 2013 Chesnelong C, Chaumeil MM, Blough MD, Al-Najjar M, Stechishin OD, Chan JA, Pieper RO, Ronen SM, Weiss S, Luchman HA, Cairncross JG
• Early Chk1 phosphorylation is driven by temozolomide-induced, DNA double strand break- and mismatch repair-independent DNA damage.
  PloS one 2013 Ito M, Ohba S, Gaensler K, Ronen SM, Mukherjee J, Pieper RO
• Pyruvate kinase M2 expression, but not pyruvate kinase activity, is up-regulated in a grade-specific manner in human glioma.
  PloS one 2013 Mukherjee J, Phillips JJ, Zheng S, Wiencke J, Ronen SM, Pieper RO
• Non-invasive in vivo assessment of IDH1 mutational status in glioma.
  Nature communications 2013 Chaumeil MM, Larson PE, Yoshihara HA, Danforth OM, Vigneron DB, Nelson SJ, Pieper RO, Phillips JJ, Ronen SM
• Evaluation of heterogeneous metabolic profile in an orthotopic human glioblastoma xenograft model using compressed sensing hyperpolarized 3D 13C magnetic resonance spectroscopic imaging.
  Magnetic resonance in medicine 2012 Park I, Hu S, Bok R, Ozawa T, Ito M, Mukherjee J, Phillips JJ, James CD, Pieper RO, Ronen SM, Vigneron DB, Nelson SJ
• Longitudinal evaluation of MPIO-labeled stem cell biodistribution in glioblastoma using high resolution and contrast-enhanced MR imaging at 14.1 tesla.
  Neuro-oncology 2012 Chaumeil MM, Gini B, Yang H, Iwanami A, Sukumar S, Ozawa T, Pieper RO, Mischel PS, James CD, Berger MS, Ronen SM
• Sensitivity of glioblastomas to clinically available MEK inhibitors is defined by neurofibromin 1 deficiency.
  Cancer research 2012 See WL, Tan IL, Mukherjee J, Nicolaides T, Pieper RO
• Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma.
  Neuro-oncology 2011 Butowski N, Chang SM, Lamborn KR, Polley MY, Pieper R, Costello JF, Vandenberg S, Parvataneni R, Nicole A, Sneed PK, Clarke J, Hsieh E, Costa BM, Reis RM, Hristova-Kazmierski M, Nicol SJ, Thornton DE,…
• NPAS3 demonstrates features of a tumor suppressive role in driving the progression of Astrocytomas.
  The American journal of pathology 2011 Moreira F, Kiehl TR, So K, Ajeawung NF, Honculada C, Gould P, Pieper RO, Kamnasaran D
• Downregulation of FIP200 induces apoptosis of glioblastoma cells and microvascular endothelial cells by enhancing Pyk2 activity.
  PloS one 2011 Wang D, Olman MA, Stewart J, Tipps R, Huang P, Sanders PW, Toline E, Prayson RA, Lee J, Weil RJ, Palmer CA, Gillespie GY, Liu WM, Pieper RO, Guan JL, Gladson CL
• Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.
  Cancer research 2011 Nakamura JL, Phong C, Pinarbasi E, Kogan SC, Vandenberg S, Horvai AE, Faddegon BA, Fiedler D, Shokat K, Houseman BT, Chao R, Pieper RO, Shannon K
• Implications for immunotherapy of tumor-mediated T-cell apoptosis associated with loss of the tumor suppressor PTEN in glioblastoma.
  Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2010 Waldron JS, Yang I, Han S, Tihan T, Sughrue ME, Mills SA, Pieper RO, Parsa AT
• Ubiquitin-specific protease 8 links the PTEN-Akt-AIP4 pathway to the control of FLIPS stability and TRAIL sensitivity in glioblastoma multiforme.
  Cancer research 2010 Panner A, Crane CA, Weng C, Feletti A, Fang S, Parsa AT, Pieper RO
• FoxM1B regulates NEDD4-1 expression, leading to cellular transformation and full malignant phenotype in immortalized human astrocytes.
  Cancer research 2010 Dai B, Pieper RO, Li D, Wei P, Liu M, Woo SY, Aldape KD, Sawaya R, Xie K, Huang S
• Gamma interferon-mediated superinduction of B7-H1 in PTEN-deficient glioblastoma: a paradoxical mechanism of immune evasion.
  Neuroreport 2009 Han SJ, Ahn BJ, Waldron JS, Yang I, Fang S, Crane CA, Pieper RO, Parsa AT
• A novel PTEN-dependent link to ubiquitination controls FLIPS stability and TRAIL sensitivity in glioblastoma multiforme.
  Cancer research 2009 Panner A, Crane CA, Weng C, Feletti A, Parsa AT, Pieper RO
• Honokiol-mediated inhibition of PI3K/mTOR pathway: a potential strategy to overcome immunoresistance in glioma, breast, and prostate carcinoma without impacting T cell function.
  Journal of immunotherapy (Hagerstown, Md. : 1997) 2009 Crane C, Panner A, Pieper RO, Arbiser J, Parsa AT
• The receptor interacting protein 1 inhibits p53 induction through NF-kappaB activation and confers a worse prognosis in glioblastoma.
  Cancer research 2009 Park S, Hatanpaa KJ, Xie Y, Mickey BE, Madden CJ, Raisanen JM, Ramnarain DB, Xiao G, Saha D, Boothman DA, Zhao D, Bachoo RM, Pieper RO, Habib AA
• p53 Small-molecule inhibitor enhances temozolomide cytotoxic activity against intracranial glioblastoma xenografts.
  Cancer research 2008 Dinca EB, Lu KV, Sarkaria JN, Pieper RO, Prados MD, Haas-Kogan DA, Vandenberg SR, Berger MS, James CD
• PI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer.
  Oncogene 2008 Crane CA, Panner A, Murray JC, Wilson SP, Xu H, Chen L, Simko JP, Waldman FM, Pieper RO, Parsa AT
• S6K1 plays a key role in glial transformation.
  Cancer research 2008 Nakamura JL, Garcia E, Pieper RO
• H-Ras increases urokinase expression and cell invasion in genetically modified human astrocytes through Ras/Raf/MEK signaling pathway.
  Glia 2008 Zhao Y, Xiao A, Dipierro CG, Abdel-Fattah R, Amos S, Redpath GT, Carpenter JE, Pieper RO, Hussaini IM
• Notch activation is associated with tetraploidy and enhanced chromosomal instability in meningiomas.
  Neoplasia (New York, N.Y.) 2008 Baia GS, Stifani S, Kimura ET, McDermott MW, Pieper RO, Lal A
• Increased expression of the glioma-associated antigen ARF4L after loss of the tumor suppressor PTEN. Laboratory investigation.
  Journal of neurosurgery 2008 Chi JH, Panner A, Cachola K, Crane CA, Murray J, Pieper RO, James CD, Parsa AT
• Glioma invasiveness responds variably to irradiation in a co-culture model.
  International journal of radiation oncology, biology, physics 2007 Nakamura JL, Haas-Kogan DA, Pieper RO
• Heat shock protein 90alpha recruits FLIPS to the death-inducing signaling complex and contributes to TRAIL resistance in human glioma.
  Cancer research 2007 Panner A, Murray JC, Berger MS, Pieper RO
• Human cytomegalovirus induces cellular tyrosine kinase signaling and promotes glioma cell invasiveness.
  Journal of neuro-oncology 2007 Cobbs CS, Soroceanu L, Denham S, Zhang W, Britt WJ, Pieper R, Kraus MH
• Contribution of Notch signaling activation to human glioblastoma multiforme.
  Journal of neurosurgery 2007 Kanamori M, Kawaguchi T, Nigro JM, Feuerstein BG, Berger MS, Miele L, Pieper RO
• Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma.
  Nature medicine 2006 Parsa AT, Waldron JS, Panner A, Crane CA, Parney IF, Barry JJ, Cachola KE, Murray JC, Tihan T, Jensen MC, Mischel PS, Stokoe D, Pieper RO
• Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain.
  PLoS medicine 2006 Lee JC, Vivanco I, Beroukhim R, Huang JH, Feng WL, DeBiasi RM, Yoshimoto K, King JC, Nghiemphu P, Yuza Y, Xu Q, Greulich H, Thomas RK, Paez JG, Peck TC, Linhart DJ, Glatt KA, Getz G, Onofrio R, …
• The PTEN/Akt pathway dictates the direct alphaVbeta3-dependent growth-inhibitory action of an active fragment of tumstatin in glioma cells in vitro and in vivo.
  Cancer research 2006 Kawaguchi T, Yamashita Y, Kanamori M, Endersby R, Bankiewicz KS, Baker SJ, Bergers G, Pieper RO
• The Mre11/Rad50/Nbs1 complex interacts with the mismatch repair system and contributes to temozolomide-induced G2 arrest and cytotoxicity.
  Molecular cancer therapeutics 2006 Mirzoeva OK, Kawaguchi T, Pieper RO
• Intracranial microenvironment reveals independent opposing functions of host alphaVbeta3 expression on glioma growth and angiogenesis.
  The Journal of biological chemistry 2006 Kanamori M, Kawaguchi T, Berger MS, Pieper RO
• DNA damaging agent-induced autophagy produces a cytoprotective adenosine triphosphate surge in malignant glioma cells.
  Cell death and differentiation 2006 Katayama M, Kawaguchi T, Berger MS, Pieper RO
• Use of APO2L/TRAIL with mTOR inhibitors in the treatment of glioblastoma multiforme.
  Expert review of anticancer therapy 2006 Panner A, Parsa AT, Pieper RO
• mTOR-independent translational control of the extrinsic cell death pathway by RalA.
  Molecular and cellular biology 2006 Panner A, Nakamura JL, Parsa AT, Rodriguez-Viciana P, Berger MS, Stokoe D, Pieper RO
• Translational regulation of TRAIL sensitivity.
  Cell cycle (Georgetown, Tex.) 2006 Panner A, Parsa AT, Pieper RO
• mTOR controls FLIPS translation and TRAIL sensitivity in glioblastoma multiforme cells.
  Molecular and cellular biology 2005 Panner A, James CD, Berger MS, Pieper RO
• Akt activation suppresses Chk2-mediated, methylating agent-induced G2 arrest and protects from temozolomide-induced mitotic catastrophe and cellular senescence.
  Cancer research 2005 Hirose Y, Katayama M, Mirzoeva OK, Berger MS, Pieper RO
• PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma.
  Cancer research 2005 Rong Y, Post DE, Pieper RO, Durden DL, Van Meir EG, Brat DJ
• PKB/Akt mediates radiosensitization by the signaling inhibitor LY294002 in human malignant gliomas.
  Journal of neuro-oncology 2005 Nakamura JL, Karlsson A, Arvold ND, Gottschalk AR, Pieper RO, Stokoe D, Haas-Kogan DA
• Convection-enhanced delivery of tumor necrosis factor-related apoptosis-inducing ligand with systemic administration of temozolomide prolongs survival in an intracranial glioblastoma xenograft model.
  Cancer research 2004 Saito R, Bringas JR, Panner A, Tamas M, Pieper RO, Berger MS, Bankiewicz KS
• Cooperative function of Chk1 and p38 pathways in activating G2 arrest following exposure to temozolomide.
  Journal of neurosurgery 2004 Hirose Y, Katayama M, Berger MS, Pieper RO
• Integrin beta3 overexpression suppresses tumor growth in a human model of gliomagenesis: implications for the role of beta3 overexpression in glioblastoma multiforme.
  Cancer research 2004 Kanamori M, Vanden Berg SR, Bergers G, Berger MS, Pieper RO
• The p38 mitogen-activated protein kinase pathway links the DNA mismatch repair system to the G2 checkpoint and to resistance to chemotherapeutic DNA-methylating agents.
  Molecular and cellular biology 2003 Hirose Y, Katayama M, Stokoe D, Haas-Kogan DA, Berger MS, Pieper RO
• Overexpression of vascular endothelial growth factor isoforms drives oxygenation and growth but not progression to glioblastoma multiforme in a human model of gliomagenesis.
  Cancer research 2003 Sonoda Y, Kanamori M, Deen DF, Cheng SY, Berger MS, Pieper RO
• Delayed repletion of O6-methylguanine-DNA methyltransferase resulting in failure to protect the human glioblastoma cell line SF767 from temozolomide-induced cytotoxicity.
  Journal of neurosurgery 2003 Hirose Y, Kreklau EL, Erickson LC, Berger MS, Pieper RO
• Akt pathway activation converts anaplastic astrocytoma to glioblastoma multiforme in a human astrocyte model of glioma.
  Cancer research 2001 Sonoda Y, Ozawa T, Aldape KD, Deen DF, Berger MS, Pieper RO
• Formation of intracranial tumors by genetically modified human astrocytes defines four pathways critical in the development of human anaplastic astrocytoma.
  Cancer research 2001 Sonoda Y, Ozawa T, Hirose Y, Aldape KD, McMahon M, Berger MS, Pieper RO
• Dual growth arrest pathways in astrocytes and astrocytic tumors in response to Raf-1 activation.
  The Journal of biological chemistry 2001 Fanton CP, McMahon M, Pieper RO
• p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells.
  Cancer research 2001 Hirose Y, Berger MS, Pieper RO
• Highly efficient cell-mediated gene transfer using non-viral vectors and FuGene6: in vitro and in vivo studies.
  Cellular and molecular life sciences : CMLS 2000 Hellgren I, Drvota V, Pieper R, Enoksson S, Blomberg P, Islam KB, Sylvén C
• Phosphatidylserine-dependent phagocytosis of apoptotic glioma cells by normal human microglia, astrocytes, and glioma cells.
  Neuro-oncology 2000 Chang GH, Barbaro NM, Pieper RO
• Presetting of chromatin structure and transcription factor binding poise the human GADD45 gene for rapid transcriptional up-regulation.
  Nucleic acids research 1999 Graunke DM, Fornace AJ, Pieper RO
• Confluence-induced alterations in CpG island methylation in cultured normal human fibroblasts.
  Nucleic acids research 1999 Pieper RO, Lester KA, Fanton CP
• Aberrant silencing of the CpG island-containing human O6-methylguanine DNA methyltransferase gene is associated with the loss of nucleosome-like positioning.
  Molecular and cellular biology 1997 Patel SA, Graunke DM, Pieper RO
• Methylation of discrete regions of the O6-methylguanine DNA methyltransferase (MGMT) CpG island is associated with heterochromatinization of the MGMT transcription start site and silencing of the gene.
  Molecular and cellular biology 1997 Watts GS, Pieper RO, Costello JF, Peng YM, Dalton WS, Futscher BW
• Understanding and manipulating O6-methylguanine-DNA methyltransferase expression.
  Pharmacology & therapeutics 1997 Pieper RO
• Methylation of CpG island transcription factor binding sites is unnecessary for aberrant silencing of the human MGMT gene.
  The Journal of biological chemistry 1996 Pieper RO, Patel S, Ting SA, Futscher BW, Costello JF
• In vitro transcription termination by N,N'-bis(2-chloroethyl)-N-nitrosourea-induced DNA lesions.
  Molecular pharmacology 1995 Pieper RO, Noftz SL, Erickson LC
• Methylation-related chromatin structure is associated with exclusion of transcription factors from and suppressed expression of the O-6-methylguanine DNA methyltransferase gene in human glioma cell lines.
  Molecular and cellular biology 1994 Costello JF, Futscher BW, Kroes RA, Pieper RO
• The role of two conserved amino acids, glutamine 90 and asparagine 137, in O6-methylguanine-DNA methyltransferase stability, activity and substrate specificity.
  Carcinogenesis 1994 Pieper RO, Morgan SE, Kelley MR
• Graded methylation in the promoter and body of the O6-methylguanine DNA methyltransferase (MGMT) gene correlates with MGMT expression in human glioma cells.
  The Journal of biological chemistry 1994 Costello JF, Futscher BW, Tano K, Graunke DM, Pieper RO
• The role of the carboxyl-terminal tail in human O6-methylguanine DNA methyltransferase substrate specificity and temperature sensitivity.
  The Journal of biological chemistry 1993 Morgan SE, Kelley MR, Pieper RO
• DNA-damaging and transcription-terminating lesions induced by AF64A in vitro.
  Journal of neurochemistry 1992 Futscher BW, Pieper RO, Barnes DM, Hanin I, Erickson LC
• Gene-specific DNA interstrand cross-links produced by nitrogen mustard in the human tumor cell line Colo320HSR.
  Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research 1992 Futscher BW, Pieper RO, Dalton WS, Erickson LC
• Expression of ribosomal phosphoprotein PO is induced by antitumor agents and increased in Mer- human tumor cell lines.
  Carcinogenesis 1992 Grabowski DT, Pieper RO, Futscher BW, Deutsch WA, Erickson LC, Kelley MR
• Direct correlation between methylation status and expression of the human O-6-methylguanine DNA methyltransferase gene.
  Cancer communications 1991 Pieper RO, Costello JF, Kroes RA, Futscher BW, Marathi U, Erickson LC
• Effects of streptozotocin/bis-chloroethylnitrosourea combination therapy on O6-methylguanine DNA methyltransferase activity and mRNA levels in HT-29 cells in vitro.
  Cancer research 1991 Pieper RO, Futscher BW, Dong Q, Erickson LC
• DNA adenine adducts induced by nitrogen mustards and their role in transcription termination in vitro.
  Carcinogenesis 1990 Pieper RO, Erickson LC
• Comparison of O-6-methylguanine DNA methyltransferase (MGMT) mRNA levels in Mer+ and Mer- human tumor cell lines containing the MGMT gene by the polymerase chain reaction technique.
  Cancer communications 1990 Pieper RO, Futscher BW, Dong Q, Ellis TM, Erickson LC
• Transcription-terminating lesions induced by bifunctional alkylating agents in vitro.
  Carcinogenesis 1989 Pieper RO, Futscher BW, Erickson LC
• Interrelationship of 3-deazaguanine-induced growth inhibitory actions in L1210 cells.
  Biochemical pharmacology 1988 Pieper RO, Mandel HG
• DNA-directed actions of 3-deazaguanine: effects on DNA integrity and DNA elongation/ligation.
  Cancer research 1988 Pieper RO, Kennedy KA, Mandel HG
• Correlation of biochemical effects and incorporation of 3-deazaguanine into nucleic acids to cytotoxicity in L1210 cells.
  Cancer research 1986 Pieper RO, Barrows LR, Mandel HG
• Gastric cancer. Factors influencing longterm survival and postoperative mortality.
  Acta chirurgica Scandinavica. Supplementum 1986 Sjöstedt S, Pieper R